Presenter Disclosure Information
|
|
- Linda O’Neal’
- 5 years ago
- Views:
Transcription
1 Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES DISCLOSURE: None
2 Prescription Drug Data: Advantages, Availability, and Access Soko Setoguchi, MD, DrPH Assistant Professor in Medicine and Epidemiology, Harvard Medical School and Harvard School of Public Health Director in Safety and Outcome Research in Cardiology Division of Pharmacoepidemiology, Brigham and Women s Hospital
3 Pharmacoepidemiology Study of the use and effects of drugs in large numbers of persons. (Strom) Adverse drug events Drug utilization patterns and adherence Drug efficacy and effectiveness Post-marketing surveillance research The goal is to provide information to support the optimal use of medications and better-informed drug therapy decisions.
4 Outline What types of health services/outcome research questions need drug use data? Different ways of assessing drug use Characteristic of different drug use data Dispensing data from large administrative databases Types of information Advantage Access Making sense of dispensing data in large databases
5 % Use of the drug within 90 days after discharge from myocardial infarction hospitalization Statin Beta blockers ACEI or ARB Year Setoguchi AJC 2007
6 60% 40% 20% 0% Non-black Black P <0.001 for Racial Difference Setoguchi AJC 2007 Percent of patients who filled the drug within 90 days after discharge from myocardial infarction hospitalization
7 1 Adherence to ACE or ARB in Patients with Heart Failure Proportion ACE ACE Lower CL ACE Upper CL Proportion ARB ARB Lower CL ARB Upper CL
8 Comparative Effectiveness Research (CER) The conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real world settings. - Federal Coordinating Council on CER
9 TNFA Increases the Risk of HF Hospitalization Compared to MTX Fully adjusted (all users) Fully adjusted (new users) Previous HF + Previous HF - Two groups Setoguchi et al AHJ 2009 combined
10 Types of Health Services/Outcome Research Questions Using Drug Data Descriptive or analytic studies assessing use, initiation, and adherence/compliance of/to prescription drug use Comparative/clinical effectiveness research involving medical treatments The Federal Coordinating Counsil definition include effectiveness and safety Drug use as an exposure
11 Characteristics of Drug Use Longitudinal and time-varying Patients are not great source of information inaccurate (do not remember, remember incorrectly, or may not tell you the truth) Inaccuracy (misclassification) may be differential Difficult to predict Multiple players (physicians, pharmacists, patients, family etc) Little variability explained by usual patients and provider characteristics
12 How Prescription Drugs Are Taken by Patients? What has to happen for patients to be able to take a prescription drug?
13 Clinicians write prescriptions and record in charts Patients go to pharmacies and pharmacists dispense prescription drugs Patients take medications
14 Different Ways of Assessing Drug Use Obtain Information on Prescriptions Medical records Electronic record of prescribing Obtain Information on Dispensing Drug files in most large databases Record # of times that patients open the bottle Patients or someone count pills Measure blood level of medications Ask Patients
15 Existing Databases Contain Different Types of Drug Use Data Prescriptions Electronic medical records, electronic prescribing data, clinical registries, GPRD Dispensing Administrative databases (Medicaid, Medicare Part D, State Pharmacy Assistance Programs, large HMOs) Bottle openings Not available in databases Pill Count Blood level Ask Patients Not available in databases Not available in databases NHANES (and see bottles or meds), population based cohort studies (Framingham, Nurses Health study etc)
16 Pros and Cons of Different Drug Data Methods Pros Cons Prescriptions Dispensing Bottle opening, blood level etc Ask patients Good source if you want to know what is prescribed (physicians behavior) vs. what is used by patients Available in large administrative databases, longitudinal, closer to actual intake than prescription data Highly accurate Can obtain additional information on reasons of use and low compliance Information is sometimes missing in charts (West SL J Clin Epi 1994) Further from actual intake No information on indications No information on actual intake Very expensive to collect data Inaccurate, differential recall by exposure or outcome status
17 Self-Reported Drug Use Patients Enrolled in a HMO for >12 years and Aged years. 57% patients recalled using NSAIDs (41% of one time user and 85% of repeated users) 30% recalled name and 15% recalled both name and dose for NSAIDs 78% recalled name and 28% recalled both name and does for estrogen West et al. Am J Epi 1995
18 Dispensing Data from Large Administrative Databases
19 Advantages of Prescription Drug Data in Administrative Databases Considered gold standard Gold standard does not indicate perfect or 100% accurate. Large Longitudinal Detailed can calculate daily dose, duration of use, adherence with some assumptions
20 Information Typically Included Drug Files in Administrative Databases Date of dispensing National drug codes Generic name Form Strength Manufacture etc. Quantity dispensed Days supply Prescriber ID Cost
21 National Drug Codes (NDC) Universal product identifies for human drugs 10 digits number Updated monthly Limited to prescription drugs and insulin products May not be on the list the firm has notified the FDA that the product is no longer being marketed the firm has not complied fully with its listing obligations and therefore its product is not included until complete information is provided.
22 NDC Can Tell you Dosage form Route of administration Active ingredients Manufacture Strength Package size and type Major drug class
23 Information Not Included in Drug Files in Most Administrative Databases Indication What is actually prescribed Overall error rate of not dispensing what is prescribed is 0.7% in Ontario Drug Benefit Databases (Levy et al Can J Clin Pharmacol 2003) Inpatient drug use Medical charts Premier Perspective Databases Inpatient administrative databases covering ~1/6 of US hospitalizations
24 Prescription Drug Data Example
25 Access to Drug Data from Large Databases with Drug Files Medicaid Medicare Part D State Pharmacy Assistance Programs United Health or BCBS National Health Insurance Data (Canadian provinces) Databases National Health Insurance Research Database (Taiwan) HIRA (Korea) GPRD or THIN (UK) How to Access the Data Purchase from CMS Purchase from CMS Negotiate/Collaborate with each program Purchase available Only through collaboration Only through collaboration Only by Korean researchers Purchase available
26 Making Sense of Drug Data
27 Longitudinal Dispensing Data NDC NDC description Disp_dt days_ supply qty_ dispensed Digitek 125mcg Tablet 2-Feb Digitek 125mcg Tablet 12-Mar Digitek 125mcg Tablet 7-Apr Digitek 125mcg Tablet 27-Jul
28 Creating A Diary
29 Creating A Diary
30 Creating A Diary
31 Prevalent Users Underascertainment of events that occur early in therapy Depletion of susceptibles survivor bias Prevalent users are adherent patients Adherence bias
32 Survivor Bias Prevalent users are those who survived through events that could have happened soon after the initiation of the therapy Prevalent users may be very different from new users
33 New-User Design All patients in a defined population (in terms of who and from which period) who initiated a treatment with the study medication Follow-up for endpoints begins at the time or initiation The study patients are further restricted to those with a minimum period of nonuse (washout) prior to the start of the drug Consider pharmacology of the therapy 6 or 12 months has been used
34 Health User Bias Patients with Preventive medications Newer more expensive medications Less frail Seek more care Follow healthcare providers recommendations Live healthier life style Have more desire to live
35 Compared to what?- importance of comparison groups Statins are wonder drugs in nonrandomized studies 50% reduction in hip fractures Improvement in cognitive status Reduced cancer risk How choice of comparison group affect the results Statins and cancer outcome
36 Glynn Epidemiology 2001
37 Statin and Cancer Linked Medicare-State pharmacy assistance-cancer registry New Users Design Chronic users Active comparison group with similar patients (statin users vs. glaucoma drug users) Exposure Definition: 3 prescription for statin during the first 180 days after the initation of statins Comparison: Initiators of glaucoma drugs with 3 prescription for glaucoma drugs during the first 180 days after the initation Setoguchi, Circ 2007
38 New Users Design, Chronic Users, Active Comparisons Comparison Glaucoma drug users Adjustment Colorectal Cancer Lower HR 95% CI Upper 95% CI Unadjusted Sex, agesq, race adjusted** Multivarible*** Antihypretensive drug users Non-statin lipid lowering drug users Unadjusted Sex, agesq, race adjusted** Multivarible*** Unadjusted Sex, agesq, race adjusted** Multivarible*** Setoguchi, Circ 2007
39 Confounding by Severity Are ACEIs effective preventing MI in patients with hypertension? Everybody has hypertension ACEIs vs. Hypertension with Diabetes and proteinuria vs. No ACEIs Uncomplicated Hypertension
40 Comparative Effectiveness Study Comparing two drugs with similar properties Everybody has hypertension Everybody has similar severity ACEIs vs. Hypertension with Diabetes and proteinuria vs. ARBs Hypertension with Diabetes and proteinuria
41 Controlling Confounding in Observational Studies Confounding Measured Confounders Unmeasured Confounders Design Restriction Matching Analysis Standardization Stratification Multivariate regression Propensity scores Marginal Structural Models Unmeasured, but measurable in substudy 2-stage sampl. Ext. adjustment Imputation Propensity score calibration Unmeasurable Design Cross-over Choice of comparison (active comparison) Analysis Instrumental variable Schneeweiss PDS 2006, modified by Setoguchi
42 Summary Dispensing data are often considered gold standard (the best available) data for drug use information Data are detailed, longitudinal, and time-varying Assumptions are needed to create a diary of drug use based on the data Careful considerations in design and analytic methods are needed for a valid study
The University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationIntegrating Effectiveness and Safety Outcomes in the Assessment of Treatments
Integrating Effectiveness and Safety Outcomes in the Assessment of Treatments Jessica M. Franklin Instructor in Medicine Division of Pharmacoepidemiology & Pharmacoeconomics Brigham and Women s Hospital
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationRole of Pharmacoepidemiology in Drug Evaluation
Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationTuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data
Tuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data Andrew Bate Senior Director, Epidemiology Group Lead, Analytics 15th Annual Meeting of the International Society
More informationProvisional Educational Session Program: ISPE s Tenth Asian Conference on Pharmacoepidemiology 2017 as at 8 August 2017 (program subject to change)
INTRODUCTORY/INTERMEDIATE EDUCATIONAL SESSION TRACK A: PRINCIPLES OF PHARMACOEPI USING LARGE DATABASES 08:45-09:30 Use of automated databases for Pharmacoepidemiology research Instructor: Vincent Lo Re,
More informationConfounding and Bias
28 th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Barcelona, Spain August 22, 2012 Confounding and Bias Tobias Gerhard, PhD Assistant Professor, Ernest Mario School
More informationDoes Variation in the Physical Characteristics of Generic Drugs Affect Patients Experiences?
Does Variation in the Physical Characteristics of Generic Drugs Affect Patients Experiences? Results from a National Survey of Pharmacists and Patients Ameet Sarpatwari, J.D., Ph.D. Instructor in Medicine,
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationValidity of data sources in pharmacoepidemiology
Validity of data sources in pharmacoepidemiology Jesper Hallas MD DrMedSc Dept of clinical pharmacology University of Southern Denmark, Odense jhallas@health.sdu.dk Disposition 1. Defining validity 2.
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informatione-module Centers for Medicaid and Medicare (CMS) Core Measures
Centers for Medicaid and Medicare (CMS) Core Measures 1 Purpose The purpose of this e-learning module is to provide education for health care providers on Core Measures. This module is not all inclusive,
More informationHypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen
Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients Lu Chen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationObservational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies
Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure
More informationPropensity Score Methods to Adjust for Bias in Observational Data SAS HEALTH USERS GROUP APRIL 6, 2018
Propensity Score Methods to Adjust for Bias in Observational Data SAS HEALTH USERS GROUP APRIL 6, 2018 Institute Institute for Clinical for Clinical Evaluative Evaluative Sciences Sciences Overview 1.
More informationReal-world data in pragmatic trials
Real-world data in pragmatic trials Harold C. Sox,MD The Patient-Centered Outcomes Research Institute Washington, DC Presenter Disclosure Information In compliance with the accrediting board policies,
More informationBias and confounding special issues. Outline for evaluation of bias
EPIDEMIOLOGI BIAS special issues and discussion of paper April 2009 Søren Friis Institut for Epidemiologisk Kræftforskning Kræftens Bekæmpelse AGENDA Bias and confounding special issues Confounding by
More informationCAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?
CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? Mette Nørgaard, Professor, MD, PhD Department of Clinical Epidemiology Aarhus Universitety Hospital Aarhus, Denmark Danish Medical Birth Registry
More informationPropensity scores and instrumental variables to control for confounding. ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD
Propensity scores and instrumental variables to control for confounding ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD WP2 WG2: aims Evaluate methods to control for observed and unobserved
More informationISPOR Good Research Practices for Retrospective Database Analysis Task Force
ISPOR Good Research Practices for Retrospective Database Analysis Task Force II. GOOD RESEARCH PRACTICES FOR COMPARATIVE EFFECTIVENESS RESEARCH: APPROACHES TO MITIGATE BIAS AND CONFOUNDING IN THE DESIGN
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationPost-marketing Surveillance of Generic Drug Usage and Substitution Patterns
Post-marketing Surveillance of Generic Drug Usage and Substitution Patterns U01FD004855 U.S. Food and Drug Administration (FDA) Office of Generic Drugs Ilene Harris, PharmD, PhD, IMPAQ (Presenter) Christine
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationRethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands
Rethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands Objectives Identify patient barriers to medication adherence. Describe the clinical and economic impact of
More informationPatient-Centered Primary Care Scorecard Measures
Patient-Centered Primary Care Scorecard Measures Acute and Chronic Care Management Measures Medication Adherence Proportion of Days Covered (PDC): Oral Diabetes Identifies patients with at least two prescriptions
More informationFDA Sentinel Initiative: Status Update and Examples of Contributions to Regulatory Decisions
FDA Sentinel Initiative: Status Update and Examples of Contributions to Regulatory Decisions Marsha E. Reichman, Ph.D. Scientific Lead for Surveillance Programs CDER Lead for the Sentinel Initiative OPE/OSE/CDER/FDA
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationThe Immediate Post-Launch Phase and Confounding by Indication or Channeling Bias: How does it affect our ability to conduct CER?
The Immediate Post-Launch Phase and Confounding by Indication or Channeling Bias: How does it affect our ability to conduct CER? Cynthia J Girman Executive Director and Head of Data Analytics & Observational
More informationState of the art pharmacoepidemiological study designs for post-approval risk assessment
State of the art pharmacoepidemiological study designs for post-approval risk assessment Cardiac Safety Research Consortium Think Tank Round Table Meeting Thursday, March 6, 2014 Jennifer L. Lund, PhD
More informationDisability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors
Outcomes, Health Policy, and Managed Care Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors Yuting Zhang, PhD, a Seo Hyon Baik, PhD, a Chung-Chou H. Chang,
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationCondition/Procedure Measure Compliance Criteria Reference Attribution Method
Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is
More informationClassification of exposure and outcome
Patrick Souverein PhD Utrecht Institute for Pharmaceutical Sciences, Utrecht University EAHP Prague 13 Sept 2014 Conflict of Interest Patrick Souverein has received unrestricted funding from the private-public
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationNonadherence to chronic medications contributes to
BRIEF REPORT Pharmacy-based Interventions to Reduce Primary Medication Nonadherence to Cardiovascular Medications Michael A. Fischer, MD, MS,* Niteesh K. Choudhry, MD, PhD,* Katsiaryna Bykov, PharmD, MS,*
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationCNODES: A Canadian Initiative
CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, Canada PROTECT Conference, EMA, London, 19 February, 2015 PROVINCE OF QUEBEC, CANADA
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationUpdate in Outpatient Medicine JNC 8, Hypertension and More
Update in Outpatient Medicine JNC 8, Hypertension and More March 6 th 2015 Robert Gluckman, MD, FACP CMO Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers Squibb GE Proctor
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationOBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Patient-centered observational analytics: New directions toward studying the effects of medical products Patrick Ryan on behalf of OMOP Research Team May 22, 2012 Observational Medical Outcomes
More informationDrug Surveillance and Effectiveness Epidemiology Research - Questions to Ask your Epidemiologist
Drug Surveillance and Effectiveness Epidemiology Research - Questions to Ask your Epidemiologist Roberta Glass, OptumInsight Life Sciences, Waltham, Massachusetts ABSTRACT As a SAS analyst starting work
More informationChapter 5. Comparator Selection
Chapter 5. Comparator Selection Soko Setoguchi, M.D., Dr.P.H. Duke Clinical Research Institute, Durham, NC Tobias Gerhard, Ph.D. Rutgers University, New Brunswick, NJ Abstract This chapter discusses considerations
More informationChallenges of Observational and Retrospective Studies
Challenges of Observational and Retrospective Studies Kyoungmi Kim, Ph.D. March 8, 2017 This seminar is jointly supported by the following NIH-funded centers: Background There are several methods in which
More informationPCORnet Use Cases. Observational study: Dabigatran vs warfarin and ischemic and hemorrhagic stroke / extra-cranial bleeding
PCORnet Use Cases Observational study: Dabigatran vs warfarin and ischemic and hemorrhagic stroke / extra-cranial bleeding 1 Observational study: Dabigatran vs warfarin and stroke / bleeding Goal: Compare
More informationImproving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help
Improving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help William Shrank MD MSHS Division of Pharmacoepidemiology & Pharmacoeconomics Harvard Medical School wshrank@partners.org
More informationPharmacy Audit Recovery Guidelines
1/1E DAW 1 DAW 1 Error The prescription order does not indicate the prescriber ordered brand name. 2 /2E DAW 2 DAW 2 Not Documented The documentation does not specify the patient s request for brand. Pharmacy
More informationMeasuring drug exposure: rationale and methods
Measuring drug exposure: rationale and methods Hubert G. Leufkens Declaration of interests Chairman of the Dutch Medicines Evaluation Board (MEB), since mid 2007. Professor of Pharmacoepidemiology, Utrecht
More informationCancer and pharmacoepidemiology in Finland. Information sources and research possibilities
Cancer and pharmacoepidemiology in Finland Information sources and research possibilities What I will talk about Register-based data sources available in Finland Register linkage method Available background
More informationStatins and newly diagnosed diabetes
DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey
More informationThe Role of the PDMP: Foundational Knowledge and Best Practices
The Role of the PDMP: Foundational Knowledge and Best Practices Brent I. Fox, PharmD, PhD Health Outcomes Research and Policy Harrison School of Pharmacy Auburn University DISCLOSURE I, Brent Fox, have
More informationLayered Approaches to Studying Drug Responses
Layered Approaches to Studying Drug Responses Brian B Hoffman, MD Chief of Medicine VA Boston Health Care System Professor of Medicine Harvard Medical School Conflict of Interest: US Federal Grant Funding
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationIncorporating External Data into Existing Longitudinal Studies
Incorporating External Data into Existing Longitudinal Studies Public Workshop: Addressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies Relying on Healthcare Databases
More informationDIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA
DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA Fran Cunningham, Pharm.D. Department of Veterans Affairs* University of Illinois at Chicago Bruce Lambert, Ph.D. University of
More informationLike others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.
Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationA Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women
A Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women APHA Conference Washington, DC November 2, 2011 Presenter Disclosures Kathy Schneider, PhD
More informationImpact of hospitalization on medication adherence estimation in claims data
Received: 23 December 2016 Accepted: 15 February 2017 DOI: 10.1111/jcpt.12517 ORIGINAL ARTICLE Impact of hospitalization on medication adherence estimation in claims data Y.-H. Dong PhD 1,2,3 N. K. Choudhry
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationThis document was created on 07 January 2005 and has been printed from
1 Spontaneous Adverse Event Reporting Information Introduction This document provides information regarding spontaneous adverse event reports received concerning patients taking rosuvastatin, which relates
More informationPharmacy practice research is
Research fundamentals Bias: Considerations for research practice Tobias Gerhard Pharmacy practice research is multifaceted and includes a variety of settings, study questions, and study designs. This report
More informationIdentifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T.
UvA-DARE (Digital Academic Repository) Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T. Link to publication Citation for published version
More informationThe Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager
The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager Objectives Core Components of Cardiac Rehab Program CR Indications &
More informationTrends in adherence to secondary prevention medications in elderly post-myocardial infarction patients y
pharmacoepidemiology and drug safety 2008; 17: 1189 1196 Published online 27 October 2008 in Wiley InterScience (www.interscience.wiley.com).1671 ORIGINAL REPORT Trends in adherence to secondary prevention
More informationRESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationConsensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0
Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationResearch. Sebastian Schneeweiss, Soko Setoguchi, Alan Brookhart, Colin Dormuth, Philip S. Wang. Methods
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients Sebastian Schneeweiss, Soko Setoguchi, Alan Brookhart, Colin Dormuth, Philip S. Wang DOI:10.1503/cmaj.061250
More informationOR OTHER RELATIONSHIP(S) DISCLOSURE:
Gregory Roth, MD DISCLOSURE DECLARATION Medication Adherence in Cardiovascular Disease: Drugs Don t Work in Patients Who Don t Take Them FINANCIAL OR OTHER RELATIONSHIP(S) DISCLOSURE: St. Charles Medical
More informationEvolution of Active Surveillance: An Industry Perspective
Evolution of Active Surveillance: An Industry Perspective Midwest Biopharmaceutical Statistics Workshop May 21, 2013 Stephen Motsko, PharmD, PhD Ken Hornbuckle, DVM, PhD Office of Risk Management and Pharmacoepidemiology
More information9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance
Pharmacy Quality Measures: Action Steps for Improvement Financial Support Financial support was provided for this activity through an unrestricted grant from Health Mart Systems, Inc. Christine Jacobson
More informationCOPYRIGHTED MATERIAL. Introduction
1 Introduction Pharmacology is the science of drugs and their effects on biological systems. A drug can be defined as a chemical that can cause a change in a biological system; the important biological
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationAddressing the Problem of Health Literacy: Practical Approaches in Practice
Addressing the Problem of Health Literacy: Practical Approaches in Practice Darren DeWalt, MD, MPH & Michael Pignone, MD, MPH University of North Carolina-Chapel Hill Department of Medicine Topics Relationship
More informationLeeds West CCG Paediatric asthma project. January 2015-January 2017
Leeds West CCG Paediatric asthma project. January 2015-January 2017 Aims to raise asthma awareness improve care reduce emergency attendances and unplanned admissions to secondary care for children with
More informationJan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X
Primary Prevention Breast Cancer Prevention Member: Mammography reminder letters to female members ages 51.5-74 who are overdue to get a mammogram Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Providers:
More informationResearch in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research David Hickam, MD, MPH Director, Clinical Effectiveness & Decision Science Program April 10, 2017 Welcome!
More informationCLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
More informationA Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom
A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom Global perspective on heart failure: what needs to change? Martin R Cowie Professor of Cardiology National
More informationHypertension Update 2014:
GSHTP Webinar Hypertension Update 2014: The Kaiser Permanente Northern California Experience Presented by: Marc Jaffe, MD Associate Clinical Professor of Medicine, UCSF Kaiser Permanente Northern California
More informationSubgroup Analyses to Determine Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs and Coxibs in Specific Patient Groups
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 59, No. 8, August 15, 2008, pp 1097 1104 DOI 10.1002/art.23911 2008, American College of Rheumatology ORIGINAL ARTICLE Subgroup Analyses to Determine
More informationSTARS SYSTEM 5 CATEGORIES
TMG STARS 2018 1 2 STARS Program Implemented in 2008 by CMS. Tool to inform beneficiaries of quality of various health plans 5-star rating system Used to adjust payments to health plans (bonus to plans
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationPros and Cons of Clinical Trials vs. Observational Studies. Beth Devine PCORP Summer Institute July 14, 2015
Pros and Cons of Clinical Trials vs. Observational Studies Beth Devine PCORP Summer Institute July 14, 2015 Outline Randomized Trials Definitions: Pragmatic-explanatory continuum indicator summary (PRECIS)
More informationApplications of Pharmacoepidemiology in General Practice 2012 Joint Conference of Drug Safety Research Centres 21 November 2012, Hong Kong
Applications of Pharmacoepidemiology in General Practice 2012 Joint Conference of Drug Safety Research Centres 21 November 2012, Hong Kong Martin CS Wong MD, MPH JC School of Public Health and Primary
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information